Weakness, MuscleMUICUAWNCT04864093
Muscular Ultrasound and Production of ICUAW
An observational study of Weakness, Muscle, run by University of Milan at 1 site in Italy.
Trial summary
Skeletal muscle weakness is a common complication of acute respiratory failure, shock and other manifestations of critical illness or injury. ICU acquired weakness (ICUAW) - an entity defined as a bundle of critically illness neuro-myopathy and disuse atrophy - is generally diagnosed on the basis of a volitional… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Weakness, Muscle
- What is being tested?
- muscular ultrasound
- How many people
- 49 participants
- Where
- 1 siteItaly
- Study dates
- 21 Jan 2021to 21 Oct 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: all ICU patients
Who may be able to join
- patients admitted to ICU witha prediction of ICU stay >7 days
Who cannot join
- Exclusion criteria included preexisting neurological weakness, pregnancy, malignancy, and those admitted for routine overnight postoperative surgical recover
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predicative Valute of Muscular Ultrasound in the Diagnosta of ICUAW in Critically Ill Patients
Skeletal muscle weakness is a common complication of acute respiratory failure, shock and other manifestations of critical illness or injury. ICU acquired weakness (ICUAW) - an entity defined as a bundle of critically illness neuro-myopathy and disuse atrophy - is generally diagnosed on the basis of a volitional, clinical strength evaluation, which however requires patient cooperation and ability to comprehend the assessor's instructions. As patients are often unconscious or uncooperative, due to sedation or delirium, such clinical diagnosis is often not possible or is delayed. A further subclassification of critical illness neuromyopathy can be achieved using detailed nonvolitional electrophysiological investigations, which can be challenging in the ICU as they require skilled personnel for both assessment and interpretation. An average Medical Research Council strength score (MRC-SS) combined for 12 specified muscle groups lower than 48 has been widely used for diagnosing ICUAW. Recent studies reported the clinical applicability of the MRC-SS in a general ICU population, in particular its clinical usefulness in predicting ICU and in-hospital patient outcomes . Moreover, interobserver agreement and clinical predictive value have already been showed (8). However, ICU general population is less likely to be able to cooperate with volitional strength assessment and more likely to have limited access to their extremities because of trauma, burns and treatment involving medical devices. For these reasons, MRC-SS may be confined to the later stages of ICU stay. Skeletal muscle ultrasound is used for the evaluation of muscular, tendon and joint disorders. It allows the evaluation of normal and pathological skeletal muscles through the measure of parameters reflecting size, such as cross sectional area (CSA) , and architecture by calculating the pennation angle, and it allows quick and repeated bedside evaluations. Despite such promising features, to date, there are few published studies that have reported the clinical applicability of the muscle ultrasound in prediction of ICUAW during the ICU stay. The principal aim of this study is to evaluate the variation of peripheral muscle ultrasound characteristics (such as CSA and pennation angle) during the ICU stay and its possible early predictive value of ICUAW as compared to the MRC-SS performed when patients are able to cooperate.
Read the detailed description
Skeletal muscle weakness is a common complication of acute respiratory failure, shock and other manifestations of critical illness or injury. ICU acquired weakness (ICUAW) - an entity defined as a bundle of critically illness neuro-myopathy and disuse atrophy - is generally diagnosed on the basis of a volitional, clinical strength evaluation, which however requires patient cooperation and ability to comprehend the assessor's instructions. As patients are often unconscious or uncooperative, due to sedation or delirium, such clinical diagnosis is often not possible or is delayed. A further subclassification of critical illness neuromyopathy can be achieved using detailed nonvolitional electrophysiological investigations, which can be challenging in the ICU as they require skilled personnel for both assessment and interpretation. An average Medical Research Council strength score (MRC-SS) combined for 12 specified muscle groups lower than 48 has been widely used for diagnosing ICUAW. Recent studies reported the clinical applicability of the MRC-SS in a general ICU population, in particular its clinical usefulness in predicting ICU and in-hospital patient outcomes . Moreover, interobserver agreement and clinical predictive value have already been showed (8). However, ICU general population is less likely to be able to cooperate with volitional strength assessment and more likely to have limited access to their extremities because of trauma, burns and treatment involving medical devices. For these reasons, MRC-SS may be confined to the later stages of ICU stay. Skeletal muscle ultrasound is used for the evaluation of muscular, tendon and joint disorders. It allows the evaluation of normal and pathological skeletal muscles through the measure of parameters reflecting size, such as cross sectional area (CSA) , and architecture by calculating the pennation angle, and it allows quick and repeated bedside evaluations. Despite such promising features, to date, there are few published studies that have reported the clinical applicability of the muscle ultrasound in prediction of ICUAW during the ICU stay. The principal aim of this study is to evaluate the variation of peripheral muscle ultrasound characteristics (such as CSA and pennation angle) during the ICU stay and its possible early predictive value of ICUAW as compared to the MRC-SS performed when patients are able to cooperate.
Materials and methods
Study design and ethical approval
observational, single-center study in a mixed medical and surgical ICU in a university teaching hospital. We will investigate the variation of CSA and pennation angle of rectus femoris over the ICU stay. Moreover, we will examine the clinical predictive value of these two variables as compared with MRC-SS at awakening. Patients 18 years of age and older who had been invasively ventilated for 48 hours were eligible for inclusion. Exclusion criteria included preexisting neurological weakness, pregnancy, malignancy, and those admitted for routine overnight postoperative surgical recovery. A flow diagram of the study is showed in figure 1.
Study protocol
At ICU admission (T1), patients underwent muscular ultrasound comprehensive of rectus femoris cross sectional area (RFCSA) and pennation angle, diaphragm, and parasternal intercostal end-expiratory thickness appraisal. At the same time, anthropometric data and biochemical parameters necessary for the calculations of severity score (Sequential organ failure assessment -SOFA (16); Simplified acute physiology score- SAPS II ; Acute Physiology and Chronic Health Evaluation - APACHE II ) were collected. All the same measures were repeated at day 3 (T3) and 7 (T7).
Anthropometric Assessment
Anthropometric measurements of body length and weight will be recorded at ICU admission. The actual body weight as reported by the patients when able to do it was collected. From anthropometric data, body mass index (BMI, kg/m2) will be calculated, while ideal body weight was calculated using a standard formula as previously described .
Muscular ultrasound
RFCSA will bemeasured by B-mode ultrasonography using an 8 MHz, 5.6 cm linear transducer array (MindRay TE-5 machine, Mindray Bio-Medical Electronics Co. Ltd. Shenzen, China), similar to the method described elsewhere (11). The pennation angle, the angle of insertion of muscle fascicles into the deep aponeurosis, of the rectus femoris will be measure on the longitudinal view by rotating the probe parallel to either the lateral or medial head of the muscle on the position where we measured CSA. To obtain precise measurements of muscle parameters, all measurements will be performed by the same sonographer (PF) with 5 years of experience . All data will be measure three times, and the average value will be used for further analysis.
Diaphragm end-expiratory thickness will be measure in the right hemi-diaphragm in the zone of apposition as described elsewhere . All ultrasound examinations will be performe using a 10-15 MHz linear transducer in B mode (MindRay TE-5 machine, Mindray Bio-Medical Electronics Co. Ltd. Shenzen, China) by the same trained operators (PF). The inferior border of the costophrenic sinus will be identifiy as the zone of transition from the artefactual representation of the lung to the visualization of diaphragm and liver. The expiratory thickening of the parasternal intercostal muscles will be assesse with a linear probe placed 3 cm laterally from the sternum, and oriented along the sagittal plane, between the 2nd and the 3rd ribs (22). Muscle thickness will be measure just above the pleural line between the inner and outermost hyperechogenic layers of the muscle fascial borders. Images will be recorde for a subsequent computer-assisted quantitative analysis performed by a trained investigator (MU), unaware of the ventilatory condition.
MRC-SS
The consciousness level of patients will be determine using the Richmond Agitation Sedation Scale, with a score from -1 to +1 being indicative of wakefulness. Awake patients will then required to demonstrate a positive response to simple one-stage commands. Successful completion of commands was followed by muscle strength assessment using the MRC-SS - a six-point grading scale ranging from 0 (no visible contraction) to 5 (normal power) applied to six upper- and lower-limb muscle groups bilaterally (25). The day upon which MRC-SS will be performe will be recorded. ICUAW is defined as an MRC-SS less than 48 out of a possible score of 60. A standardized protocol for performing the MRC-SS will be always followed during testing. Given the volitional nature of manual muscle testing, strong verbal encouragement will be provided during all strength assessments.
statistical analysis
The computation of the study power isbased on the primary outcome (prediction of ICU-acquired weakness). A previous study found a correlation between diaphragm ultrasound and the development of ICU-acquired weakness of r=0.3. Since the current study also assesses peripheral muscle ultrasound, we hypothesized that a stronger correlation (about twice that found in the cited study) could be found with 80% power at a 5% significance level by enrolling 47 patients.
Data will be analyzed using Stata/SE 12.0 (StataCorp, College Station, TX USA) statistical software package. Two-tailed P-values <0.05 will be considered statistically significant. Normality will be assessed by the Shapiro-Francia test. Results will be reported as mean ± standard deviation if normally distributed, or median [25-75th percentiles] otherwise, and differences will be tested with a two-sided t test or the MannWhitney U test. Categorical variables are expressed as counts and percentage and the Chi-square or Fischer exact test will be used for analysis.
- Conditions
- Weakness, Muscle
- Being tested
- muscular ultrasound
- Medical subject headings
- Muscle Weakness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
muscular ultrasoundDiagnostic test
respiratroy and muscular ultrasound
What is being measured
The primary outcome is the main question the study is designed to answer.
muscular reduction over the time
Muscular ultrasound detect a muscles reduction over the time
Measured: One year
Secondary outcomes (1)
muscular ultrasond predictivity of ICUAW
Muscular ultrasound evauation anticipate the diagnosta of ICUAW
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2021
- Study start21 Jan 2021
- Primary completion21 Oct 2021
- Study completion21 Oct 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Weakness, MuscleStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 49 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Milan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Davide Chiumello, University of Milan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04864093
- Sponsor's protocol ID
- Umilan@
- Acronym
- MUICUAW
- Status last verified
- Apr 2022
- First submitted
- 22 Apr 2021
- Last updated
- 26 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predicative Valute of Muscular Ultrasound in the Diagnosta of ICUAW in Critically Ill Patients
- ClinicalTrials.gov ID
- NCT04864093
- Acronym / sponsor ID
- MUICUAW / Umilan@
- Conditions
- Weakness, Muscle
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 49 participants (actual)
- Lead sponsor
- University of MilanUniversity, hospital or other
- Study start
- 21 Jan 2021 (actual)
- Primary completion
- 21 Oct 2021 (actual)
- Study completion
- 21 Oct 2021 (actual)
- First posted
- 28 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Skeletal muscle weakness is a common complication of acute respiratory failure, shock and other manifestations of critical illness or injury. ICU acquired weakness (ICUAW) - an entity defined as a bundle of critically illness neuro-myopathy and disuse atrophy - is generally diagnosed on the basis of a volitional, clinical strength evaluation, which however requires patient cooperation and ability to comprehend the assessor's instructions. As patients are often unconscious or uncooperative, due to sedation or delirium, such clinical diagnosis is often not possible or is delayed. A further subclassification of critical illness neuromyopathy can be achieved using detailed nonvolitional electrophysiological investigations, which can be challenging in the ICU as they require skilled personnel for both assessment and interpretation. An average Medical Research Council strength score (MRC-SS) combined for 12 specified muscle groups lower than 48 has been widely used for diagnosing ICUAW. Recent studies reported the clinical applicability of the MRC-SS in a general ICU population, in particular its clinical usefulness in predicting ICU and in-hospital patient outcomes . Moreover, interobserver agreement and clinical predictive value have already been showed (8). However, ICU general population is less likely to be able to cooperate with volitional strength assessment and more likely to have limited access to their extremities because of trauma, burns and treatment involving medical devices. For these reasons, MRC-SS may be confined to the later stages of ICU stay. Skeletal muscle ultrasound is used for the evaluation of muscular, tendon and joint disorders. It allows the evaluation of normal and pathological skeletal muscles through the measure of parameters reflecting size, such as cross sectional area (CSA) , and architecture by calculating the pennation angle, and it allows quick and repeated bedside evaluations. Despite such promising features, to date, there are few published studies that have reported the clinical applicability of the muscle ultrasound in prediction of ICUAW during the ICU stay. The principal aim of this study is to evaluate the variation of peripheral muscle ultrasound characteristics (such as CSA and pennation angle) during the ICU stay and its possible early predictive value of ICUAW as compared to the MRC-SS performed when patients are able to cooperate.
Detailed description
Skeletal muscle weakness is a common complication of acute respiratory failure, shock and other manifestations of critical illness or injury. ICU acquired weakness (ICUAW) - an entity defined as a bundle of critically illness neuro-myopathy and disuse atrophy - is generally diagnosed on the basis of a volitional, clinical strength evaluation, which however requires patient cooperation and ability to comprehend the assessor's instructions. As patients are often unconscious or uncooperative, due to sedation or delirium, such clinical diagnosis is often not possible or is delayed. A further subclassification of critical illness neuromyopathy can be achieved using detailed nonvolitional electrophysiological investigations, which can be challenging in the ICU as they require skilled personnel for both assessment and interpretation. An average Medical Research Council strength score (MRC-SS) combined for 12 specified muscle groups lower than 48 has been widely used for diagnosing ICUAW. Recent studies reported the clinical applicability of the MRC-SS in a general ICU population, in particular its clinical usefulness in predicting ICU and in-hospital patient outcomes . Moreover, interobserver agreement and clinical predictive value have already been showed (8). However, ICU general population is less likely to be able to cooperate with volitional strength assessment and more likely to have limited access to their extremities because of trauma, burns and treatment involving medical devices. For these reasons, MRC-SS may be confined to the later stages of ICU stay. Skeletal muscle ultrasound is used for the evaluation of muscular, tendon and joint disorders. It allows the evaluation of normal and pathological skeletal muscles through the measure of parameters reflecting size, such as cross sectional area (CSA) , and architecture by calculating the pennation angle, and it allows quick and repeated bedside evaluations. Despite such promising features, to date, there are few published studies that have reported the clinical applicability of the muscle ultrasound in prediction of ICUAW during the ICU stay. The principal aim of this study is to evaluate the variation of peripheral muscle ultrasound characteristics (such as CSA and pennation angle) during the ICU stay and its possible early predictive value of ICUAW as compared to the MRC-SS performed when patients are able to cooperate.
Materials and methods
Study design and ethical approval
observational, single-center study in a mixed medical and surgical ICU in a university teaching hospital. We will investigate the variation of CSA and pennation angle of rectus femoris over the ICU stay. Moreover, we will examine the clinical predictive value of these two variables as compared with MRC-SS at awakening. Patients 18 years of age and older who had been invasively ventilated for 48 hours were eligible for inclusion. Exclusion criteria included preexisting neurological weakness, pregnancy, malignancy, and those admitted for routine overnight postoperative surgical recovery. A flow diagram of the study is showed in figure 1.
Study protocol
At ICU admission (T1), patients underwent muscular ultrasound comprehensive of rectus femoris cross sectional area (RFCSA) and pennation angle, diaphragm, and parasternal intercostal end-expiratory thickness appraisal. At the same time, anthropometric data and biochemical parameters necessary for the calculations of severity score (Sequential organ failure assessment -SOFA (16); Simplified acute physiology score- SAPS II ; Acute Physiology and Chronic Health Evaluation - APACHE II ) were collected. All the same measures were repeated at day 3 (T3) and 7 (T7).
Anthropometric Assessment
Anthropometric measurements of body length and weight will be recorded at ICU admission. The actual body weight as reported by the patients when able to do it was collected. From anthropometric data, body mass index (BMI, kg/m2) will be calculated, while ideal body weight was calculated using a standard formula as previously described .
Muscular ultrasound
RFCSA will bemeasured by B-mode ultrasonography using an 8 MHz, 5.6 cm linear transducer array (MindRay TE-5 machine, Mindray Bio-Medical Electronics Co. Ltd. Shenzen, China), similar to the method described elsewhere (11). The pennation angle, the angle of insertion of muscle fascicles into the deep aponeurosis, of the rectus femoris will be measure on the longitudinal view by rotating the probe parallel to either the lateral or medial head of the muscle on the position where we measured CSA. To obtain precise measurements of muscle parameters, all measurements will be performed by the same sonographer (PF) with 5 years of experience . All data will be measure three times, and the average value will be used for further analysis.
Diaphragm end-expiratory thickness will be measure in the right hemi-diaphragm in the zone of apposition as described elsewhere . All ultrasound examinations will be performe using a 10-15 MHz linear transducer in B mode (MindRay TE-5 machine, Mindray Bio-Medical Electronics Co. Ltd. Shenzen, China) by the same trained operators (PF). The inferior border of the costophrenic sinus will be identifiy as the zone of transition from the artefactual representation of the lung to the visualization of diaphragm and liver. The expiratory thickening of the parasternal intercostal muscles will be assesse with a linear probe placed 3 cm laterally from the sternum, and oriented along the sagittal plane, between the 2nd and the 3rd ribs (22). Muscle thickness will be measure just above the pleural line between the inner and outermost hyperechogenic layers of the muscle fascial borders. Images will be recorde for a subsequent computer-assisted quantitative analysis performed by a trained investigator (MU), unaware of the ventilatory condition.
MRC-SS
The consciousness level of patients will be determine using the Richmond Agitation Sedation Scale, with a score from -1 to +1 being indicative of wakefulness. Awake patients will then required to demonstrate a positive response to simple one-stage commands. Successful completion of commands was followed by muscle strength assessment using the MRC-SS - a six-point grading scale ranging from 0 (no visible contraction) to 5 (normal power) applied to six upper- and lower-limb muscle groups bilaterally (25). The day upon which MRC-SS will be performe will be recorded. ICUAW is defined as an MRC-SS less than 48 out of a possible score of 60. A standardized protocol for performing the MRC-SS will be always followed during testing. Given the volitional nature of manual muscle testing, strong verbal encouragement will be provided during all strength assessments.
statistical analysis
The computation of the study power isbased on the primary outcome (prediction of ICU-acquired weakness). A previous study found a correlation between diaphragm ultrasound and the development of ICU-acquired weakness of r=0.3. Since the current study also assesses peripheral muscle ultrasound, we hypothesized that a stronger correlation (about twice that found in the cited study) could be found with 80% power at a 5% significance level by enrolling 47 patients.
Data will be analyzed using Stata/SE 12.0 (StataCorp, College Station, TX USA) statistical software package. Two-tailed P-values <0.05 will be considered statistically significant. Normality will be assessed by the Shapiro-Francia test. Results will be reported as mean ± standard deviation if normally distributed, or median [25-75th percentiles] otherwise, and differences will be tested with a two-sided t test or the MannWhitney U test. Categorical variables are expressed as counts and percentage and the Chi-square or Fischer exact test will be used for analysis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- all ICU patients
Key inclusion criteria (1 listed)
- patients admitted to ICU witha prediction of ICU stay >7 days
Key exclusion criteria (1 listed)
- Exclusion criteria included preexisting neurological weakness, pregnancy, malignancy, and those admitted for routine overnight postoperative surgical recover
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| muscular ultrasoundrespiratroy and muscular ultrasound | Diagnostic test | – |
Primary outcome
muscular reduction over the time
Time frame: One year
Muscular ultrasound detect a muscles reduction over the time
1 secondary outcome
muscular ultrasond predictivity of ICUAW
Time frame: One year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Apr 2022.
- Individual participant dataSharing planned: No
Related trials for Weakness, Muscle
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Active, not recruitingPhase 1
E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults
Rotator Cuff Tears, Muscle Atrophy or Weakness
Recruiting
Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients
Mobility Limitation, Frailty
Recruiting
Blood Flow Restriction Training for Mechanically Ventilated Patients With ICU-Acquired Weakness
Intensive Care Unit Acquired Weakness
Active, not recruitingPhase 2
TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status
Pre-Frailty, Sarcopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Weakness, Muscle, run by University of Milan at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
muscular reduction over the time (time frame: One year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2022.